Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 for Relapse Prevention in Ulcerative Colitis
NCT04373473Phase 2Recruiting
- Sponsor
- UTHealth Houston
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRIM-DJ2727 in ulcerative colitis (UC), sponsored by UTHealth Houston. Primary endpoint: Clinical Remission at 9 months. Started Sep 2020; status: recruiting.
02
Drugs
PRIM-DJ2727
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04373473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373473.